Controlling and conquering incurable metastatic cancer by targeting the major tumor-driving K-RAS/SIAH pathway activation to stratify patients, identify resistant tumor clones, quantify therapy efficacy, forecast tumor relapse, and predict patient survival in the neoadjuvant settings Meeting Abstract

authors

publication date

  • April 1, 2019

webpage

published in

start page

  • 146

end page

  • 147

volume

  • 36

issue

  • 2